Detroit MI 多发性骨髓瘤临床试验
19项针对 多发性骨髓瘤的研究正在 Detroit及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Karmanos Cancer Institute, Detroit
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
招募中3 期
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
招募中4 期
- Barbara Ann Karmanos Cancer Institute, Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- Henry Ford Health Saint John Hospital, Detroit
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
招募中3 期
- Henry Ford Health System, Detroit
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- Henry Ford Health Saint John Hospital, Detroit
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
招募中1/2 期
- Karmanos Cancer Institute, Detroit
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
招募中1/2 期
- Research Site, Detroit
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Detroit
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
招募中2 期
- Karmanos Cancer Institute, Detroit
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
招募中1 期
- Karmanos Cancer Institute, Detroit
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
招募中4 期
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
招募中2 期
- Karmanos Cancer Institute, Detroit
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Ascension Saint John Hospital, Detroit
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
招募中1 期
- Karmanos Cancer Institute, Detroit
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
招募中1/2 期
- Karmanos Cancer Institute, Detroit
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
招募中3 期
- GSK Investigational Site, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
招募中
- Karmanos Cancer Institute, Detroit
其他城市的 多发性骨髓瘤试验
- New York City, NY60 项研究
- Boston, MA42 项研究
- Atlanta, GA41 项研究
- Houston, TX38 项研究
- Durham, NC37 项研究
- Nashville, TN32 项研究
- Denver, CO27 项研究
- Rochester, MN24 项研究
- St. Louis, MO24 项研究
- Columbus, OH24 项研究
- Baldwin Park, CA23 项研究
- Chicago, IL22 项研究
Detroit的其他研究
- 非小细胞肺癌44 项研究
- 乳腺癌33 项研究
- 癌症（所有类型）29 项研究
- 结直肠癌26 项研究
- 卵巢癌26 项研究
- 转移性癌症24 项研究
- 前列腺癌22 项研究
- 子宫内膜癌21 项研究
- 肺癌20 项研究
- 胃癌16 项研究
- 头颈鳞状细胞癌15 项研究
- 急性髓系白血病14 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。